Selective EGF-Receptor Inhibition in CD4+ T Cells Induces Anergy and Limits Atherosclerosis
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Ligand-Independent EGFR SignalingCancer Research, 2015
- Amphiregulin Enhances Regulatory T Cell-Suppressive Function via the Epidermal Growth Factor ReceptorImmunity, 2013
- Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeuticsMolecular Cancer, 2010
- Activation of EGFR on monocytes is required for human cytomegalovirus entry and mediates cellular motilityProceedings of the National Academy of Sciences, 2009
- EGFR Antagonists in Cancer TreatmentNew England Journal of Medicine, 2008
- Erlotinib in non-small-cell lung cancerExpert Opinion on Pharmacotherapy, 2007
- Erlotinib in cancer treatmentAnnals of Oncology, 2007
- The epidermal growth factor receptors and their family of ligands: Their putative role in atherogenesisAtherosclerosis, 2006
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Does Not Improve Paclitaxel Effect in an Orthotopic Mouse Model of Lung CancerClinical Cancer Research, 2004
- Rho-Associated Protein Kinase Contributes to Early Atherosclerotic Lesion Formation in MiceCirculation Research, 2003